Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
7.76
+0.06 (0.78%)
At close: Nov 13, 2026, 4:00 PM EST
7.55
-0.21 (-2.71%)
After-hours: Nov 13, 2026, 7:30 PM EST
Avalo Therapeutics Revenue
In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%. That makes Avalo Therapeutics the 46,478th largest company in the world by revenue and 6,923rd in the United States.
Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
7,605.21
Revenue / Employee
$1,788
Employees
33
Market Cap
448.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.00K | -382.00K | -86.62% |
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -11.58M | -63.17% |
| Dec 31, 2018 | 18.33M | -9.49M | -34.11% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.27% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Arvinas | 275.30M |
| Gyre Therapeutics | 110.06M |
| Assembly Biosciences | 67.01M |
| CytomX Therapeutics | 14.03M |
| Ovid Therapeutics | 1.45M |
| Oculis Holding AG | 1.12M |
| Shattuck Labs | 1.00M |
AVTX News
- 4 days ago - Avalo Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 6 days ago - Avalo Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - Avalo Therapeutics price target lowered to $20 from $22 at Wedbush - TheFly
- 9 days ago - Avalo Therapeutics price target lowered to $24 from $29 at BofA - TheFly
- 10 days ago - Avalo Therapeutics files automatic mixed securities shelf - TheFly
- 10 days ago - Avalo Therapeutics reports Q3 EPS (34c), consensus (55c) - TheFly
- 10 days ago - Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates - GlobeNewsWire
- 10 days ago - Avalo Therapeutics Quarterly report: Q3 2026 - Filings